Novo Nordisk rebrand to Novo and corporate restructuring 2026
One page that accretes the verified record as the story develops. Every fact keeps its date and its sources.
Novo's next chapter as Eli Lilly gains ground in GLP-1s
Novo says its Wegovy pill has reached 7 million U.S. prescriptions, with 90% of those sales coming through cash-pay channels.
Ricks said 70% of Medicare patients who started GLP-1s are on Lilly's drugs.
Lilly said in August it held about a 61% share in the U.S. GLP-1 space in the second quarter, while Novo held roughly 39%.
Pharma stock soars 150% on injectables deal with Novo
The deal grants Novo Nordisk exclusive rights for up to five development programs to use Nanexa's PharmaShell technology.
The groups are targeting monthly and quarterly administration of the drugs.
Nanexa trades on the Nasdaq First North Growth Market in Stockholm.
Novo Nordisk's new strategy depends on regaining investor trust
Novo Nordisk announced plans to launch more than five potential blockbuster drugs by 2030 at its Capital Markets Day on Monday.
Sydbank analyst Soren Hansen said Novo's Capital Markets Day announcements were 'all about trust.'
Citi reiterated its neutral rating on Novo Nordisk stock.
Novo Nordisk CEO defends diversification push beyond obesity
Novo Nordisk outlined plans to release over five "multi-blockbuster" drugs by 2030.
Eli Lilly CEO David Ricks said a third of new GLP-1 patients are taking its oral weight loss pill, Foundayo.
Novo Nordisk CEO Mike Doustdar said the company is considering M&A opportunities.
Novo Nordisk shares slide as drugmaker lays out post-Wegovy strategy
In August, Novo said it expects adjusted sales and operating profit to both be down 6% to flat in 2026 at constant exchange rates.
Eli Lilly shares gained 52% over the past 12 months as of Monday's opening bell.
Novo shares fell on Monday after the company laid out its long-term growth strategy.
Novo Nordisk rebrands to 'Novo' and unveils corporate changes
The company recently scrapped three trials on an experimental cardiovascular drug.
Novo Nordisk said it is rebranding its name to "Novo".
The oral version of Wegovy surpassed 3 million prescriptions as of June.